Beta-adrenergic receptor blocker propranolol triggers anti-tumor immunity and enhances irinotecan therapy in mice colorectal cancer - Lin, Yanting; Liu, Yiming; Gao, Zhenhua; Jing, Dongquan; Bi, Ran; Cui, Xinmeng; Cao, Qiuhua; Zhao, Qixiang; Gao, Rui; Su, Yali; Liu, Siliang; Zhao, Mingrui; et al. (European journal of pharmacology, 2023)
Keywords: Adrenergic beta-Antagonists - pharmacology; Adrenergic beta-Antagonists - therapeutic use; Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colorectal Neoplasms - pathology; CRC; Drug repurposing; Irinotecan - pharmacology; Irinotecan - therapeutic use; Mice; Mice, Nude; Propranolol; Propranolol - pharmacology; Propranolol - therapeutic use; T-cell exhaustion; Drug repurposing; T-cell exhaustion; Propranolol; CRC